Results 111 to 120 of about 4,805 (202)

Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer [PDF]

, 2023
Valabrega, Giorgio
core   +1 more source

Safety assessment of selinexor: a real-world pharmacovigilance study

Expert Opinion on Drug Safety
Selinexor is approved for the treatment of relapsed or refractory multiple myeloma. However, a comprehensive understanding of adverse events associated with selinexor is lacking. Clinical trials of selinexor in patients with multiple myeloma were reviewed.
Wei, Zhang, Kai, Tao, Bin, Zeng, Linghui, Deng, Ping, Lu, Ting, Niu, Shi, Qiu, Lu, Yang   +7 more
openaire   +2 more sources

Nuclear to Cytoplasmic Transport Is a Druggable Dependency in HDAC7‐driven Small Cell Lung Cancer

Advanced Science
Immunotherapy has gained approval for use in small cell lung cancer (SCLC), yet only a subset of patients (10–20%) experience meaningful benefits, underscoring the urgent need for more effective therapeutic approaches.
Tingting Qin, Jingya Wang, Jian Wang, Qingwu Du, Liuchun Wang, Hailin Liu, Wenting Liu, Xueyang Li, Yantao Jiang, Qi Xu, Junjie Yu, Huiyan Liu, Ting Wang, Mengjie Li, Dingzhi Huang   +14 more
doaj   +1 more source

Refining the role of selinexor in multiple myeloma: strategic use in a shifting treatment landscape. [PDF]

ESMO Open
Gay F, Buda G, Petrucci MT, Bolli N, Cea M, Derudas D, Mangiacavalli S, Montefusco V, Antonioli E, Barilà G, Basso M, Bertazzoni P, Bertuglia G, Bianco R, Carlisi M, Giudice MLD, Della Pepa R, Fazio F, Franceschini L, Furlan A, Gozzetti A, Liberatore C, Mancuso K, Martino EA, Mele G, Monaco F, Morè S, Paris L, Pavan L, Pezzatti S, Rago A, Ribolla R, Roncato R, Rossini B, Sgherza N, Vassallo F, Vincelli DI, Za T, Musto P, Zamagni E.   +39 more
europepmc   +1 more source

Selinexor (Xpovio™)

Oncology Times, 2020
openaire   +2 more sources

In reply: Why selinexor remains a subpar option? [PDF]

Oncologist
Mohyuddin GR, Meirson T.
europepmc   +1 more source

Prolonged XPO1 inhibition is essential for optimal anti-leukemic activity in NPM1-mutated AML [PDF]

, 2021
Bigerna, Barbara, Brunetti, Lorenzo, Caruso, Simona, Falini, Brunangelo, Gagliardi, Andrea, Landesman, Yosef, Locatelli, Franco, Marra, Andrea, Martelli, Maria Paola, Mezzasoma, Federica, Pianigiani, Giulia, Quintarelli, Concetta, Rocchio, Francesca, Shacham, Sharon, Spinozzi, Giulio, Sportoletti, Paolo, Tini, Valentina   +16 more
core   +1 more source

Selinexor enhances the sensitivity of hepatocellular carcinoma cells to sorafenib by regulating the BAX/Bcl-2/PUMA apoptotic pathway and the XPO1/p27 cell cycle pathway. [PDF]

Front Oncol
Du S, Wang L, Chen C, Sun Y, Liu Q, Shi J, Zhang F, Wang K, Cui C.   +8 more
europepmc   +1 more source

Comment on "how the addition of selinexor/bortezomib/dexamethasone as a Category 1 recommendation may erode outcomes". [PDF]

Oncologist
Richter J, Davis M, Chai Y.
europepmc   +1 more source

Efficacy of an XPO1 inhibitor in combination with irinotecan in a preclinical colorectal cancer model. [PDF]

Front Oncol
Lentz RW, Dominguez ATA, Balmaceda NB, Arcaroli JJ, Bagby SM, Binns CA, Smoots SG, Jackson MM, Macbeth M, Holmstoen T, Banerjee T, Whitty PA, Yi SS, Lieu CH, Messersmith WA, Pitts TM.   +15 more
europepmc   +1 more source